Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

BioArctic

- PMLiVE

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s

Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients

- PMLiVE

Lilly and Indiana University collaborate to expand clinical trial access

The five-year agreement includes a focus on R&D for Alzheimer’s disease

- PMLiVE

Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

While the trials did not meet their primary endpoints, they highlighted important biomarker findings

- PMLiVE

Vandria announces positive phase 1 data for Alzheimer’s treatment

Trial data showed that VNA-318 has the ability to penetrate the brain

- PMLiVE

Eisai submits new drug application for subcutaneous Leqembi in Japan

LEQEMBI is a treatment for early Alzheimer’s disease

- PMLiVE

Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

- PMLiVE

Lilly’s early Alzheimer’s disease treatment approved in the EU

Marketing authorisation follows positive late-stage trial results

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

- PMLiVE

Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing

The neurodegenerative disease affects almost seven million people in the US

Biogen Idec building

Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug

The injection process for subcutaneous Leqembi is expected to take an average of 15 seconds

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links